MyHealthChecked PLC - Final Results
MyHealthChecked PLC
("MyHealthChecked" or the "Company")
Final Results
Posting of Annual Report & Notice of AGM
MyHealthChecked PLC (AIM: MHC), the consumer home-testing healthcare company, announces its audited final results for the year ended
Financial Highlights
|
● |
Revenue of |
|
● |
Adjusted EBITDA loss of |
|
● |
VAT reclaim of |
|
● |
Cash balance at year end of |
Commercial and operational highlights
|
● |
Ongoing strong strategic relationship with Boots |
|
● |
Unit sales of wellness tests up 92% on prior year - whilst positive long-term growth potential, this category remains in its infancy with awareness raising a key future priority |
|
● |
Phlebotomy kit registered and operations in place for launch of service |
|
● |
Distribution agreement for Heart Health self-test ("PocDoc") which listed on www.boots.com in |
|
● |
End-user sales of COVID LFTs continue to reduce |
|
● |
Continued investment in the MHC digital platform providing strong ongoing digital capability |
|
● |
Achievement of ISO 13485 and ISO 27001 certifications |
The full Group Annual Report and Audited Financial Statements will be posted to shareholders today and will also be available shortly at https://investors.myhealthchecked.com/investors/annual-interim-reports
Commenting on Outlook
"Although sales of wellness tests in the current year to date have increased by approximately 62% over the comparable period in the prior year, demand for COVID LFTs by end users has continued to reduce. Despite tight cost controls the loss for H1 of the current year is therefore expected to be broadly comparable to the prior year. However, we will continue to drive towards long-term growth in consumer wellness testing.
"As an organisation with deep retail product knowledge, the board recognizes the importance of partnerships with trusted retail brands, with the key to long-term profitable growth embedded in the end-to-end customer journey, which firmly places testing as part of a wider service and product offering and builds a longer-term relationship with the end customer. We are confident that our ongoing relationship with Boots will continue, and we expect our digital platform will be used to underpin communications with customers regarding testing services. Our digital platform is able to integrate a wide portfolio of products and is a critical enabler in the delivery of higher margin services in the rest of the consumer wellness value chain, and we will continue to explore potential opportunities and strategic partnerships with
Publication of Annual Report & Audit Financial Statement ("Annual Report") & Notice of Annual General Meeting
The Annual Report and Audited Financial Statements will be posted to shareholders today. The Annual General Meeting ("AGM") will be held at
The Annual Report and Notice of AGM will be available online shortly here:
https://investors.myhealthchecked.com/
For further information contact:
|
MyHealthChecked PLC |
|||
|
Penny McCormick, Chief Executive Officer |
via Walbrook PR |
||
|
|
|
||
|
SPARK Advisory Partners Limited (NOMAD) |
Tel: +44 (0)20 3368 3550 |
||
|
|
|
||
|
|
|
||
|
Dowgate Capital Limited (Broker) |
Tel: +44 (0)20 3903 7715 |
||
|
|
|
||
|
|
|
||
|
Walbrook PR Ltd (Media & IR) |
Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com |
||
|
|
Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654 |
||
About MyHealthChecked PLC (www.myhealthcheckedplc.com)
MyHealthChecked PLC, based in
MyHealthChecked is the umbrella brand of a range of at-home rapid tests, as well as DNA, RNA and blood sample collection kits which have been created to support customers on their journeys to wellness. The tests are lateral-flow self-tests, whilst the sample collection kits enable the collection of blood, urine, nasal or mouth swab samples that are analysed in partner laboratories for a range of biomarkers. The tests have been made available online and for over-the-counter purchase.
The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by
JOINT CHAIRMAN AND CHIEF EXECUTIVE'S REPORT
During 2024 the Company has continued to focus on retail sales of its wellness portfolio. As the healthcare landscape has evolved, the growth potential for at-home and in-store testing to meet a major need within the
MHC has focused heavily in recent years on working with Boots - the
As previously reported sales of COVID Lateral Flow Tests ("LFTs") were significantly reduced during 2024 due to high stock levels in trade at the start of the year which meant the initial orders in preparation of the 24/25 season were not received until July. Furthermore, since the spike in demand seen last summer, end-user sales of COVID LFTs have continued to reduce from the levels seen in prior years and this trend is now expected to continue reflecting a change in decision-making post-vaccine and an associated shift in testing habits as the virus is assumed to be of less concern to individuals.
However, following the successful launch of the wellness portfolio in 2023 growth has been consistent, and unit sales of the range overall have almost doubled compared to the prior year. Lateral flow tests provide a price-accessible entry-level proposition, whilst the laboratory test range offers a more in-depth wellness assessment, and together this varied portfolio is comprehensive and underpins the broader testing category at point of sale. It is expected that sales will continue to grow as integration into wider healthcare services is maximized by the potential of the MHC digital platform.
With home testing still in its early stages and the growth potential yet to be realized, we have worked closely with Boots to distribute a pipeline of tests that are innovative, and benefit the end-user, to form part of a wider testing and services portfolio. During the year under review, we identified two such tests; the first was a rapid HIV test from Newfoundland Diagnostics that requires a small blood sample taken by a novel device with an inbuilt lancet and capillary action. This simple-to-use and affordable test has performed very well at retail and has been designed to facilitate an affordable testing process for users with the aim of encouraging regular testing as part of a proactive HIV management programme. We also signed a contract with Vital Signs Solutions Limited to distribute their groundbreaking connected Heart Health self-test ("PocDoc"), which listed on www.boots.com in
Portfolio expansion
Presently MHC branded products sit alongside Boots own brand products in store. However, as the category has grown, we have noted that the addition of retailer private label brands, such as
Digital development
We have continued to invest in the MHC digital platform, building a scalable platform with a robust recommendation engine that can underpin the variety of test types and services in our portfolio and enable omnichannel delivery. The platform has been built for retail customers from inception and is highly customer-centric to ensure a seamless experience for users. We have continued to build upon its capabilities to ensure that the development of new test types, pathways and recommendations can be delivered efficiently, which will in turn accelerate route to market. We have undertaken works in 2024 under tight cost control and have evolved our operational infrastructure so that our ongoing digital capability is strong.
Data security
During the period we also built upon our Cyber Essentials Plus certification introducing robust security and testing practices and systems to achieve ISO 27001:2013 accreditation in
Regulatory compliance
In
Outlook
Although sales of wellness tests in the current year to date have increased by approximately 62% over the comparable period in the prior year, demand for COVID LFTs by end users has continued to reduce. Despite tight cost controls the loss for H1 of the current year is therefore expected to be broadly comparable to the prior year. However, we will continue to drive towards long-term growth in consumer wellness testing.
As an organisation with deep retail product knowledge, the board recognizes the importance of partnerships with trusted retail brands, with the key to long-term profitable growth embedded in the end-to-end customer journey, which firmly places testing as part of a wider service and product offering and builds a longer-term relationship with the end customer. We are confident that our ongoing relationship with Boots will continue, and we expect our digital platform will be used to underpin communications with customers regarding testing services. Our digital platform is able to integrate a wide portfolio of products and is a critical enabler in the delivery of higher margin services in the rest of the consumer wellness value chain, and we will continue to explore potential opportunities and strategic partnerships with
FINANCIAL REVIEW
Income statement
Revenue for the year amounted to approximately
Gross margin fell from a profit of
Total spend on the development and maintenance of IT infrastructure during the year amounted to
Sales and marketing costs were broadly comparable to the prior year at
The Group's operating loss amounted to
During the year the Company also submitted a claim to HMRC for the repayment of VAT levied on certain COVID PCR tests sold in earlier years. As certain elements of the claim have been accepted exceptional income of
After the exceptional income, net interest income of
Adjusted EBITDA is calculated as follows:
|
|
2024 |
2023 |
|
|
£'000 |
£'000 |
|
Operating loss |
(2,230) |
(361) |
|
Non-cash movement in provisions and accruals |
- |
(1,165) |
|
Depreciation, amortisation and profit/(loss) on disposal of equipment |
249 |
224 |
|
Share based payments |
54 |
38 |
|
Adjusted EBITDA |
(1,927) |
(1,264) |
Financial position
The Group's net assets as at
Cashflow
The Group's cash balance at the year-end was
Capital management
The Board's objective is to maintain a balance sheet that is both efficient and delivers long-term shareholder value. The Board continues to monitor the balance sheet to ensure it has an adequate capital structure.
Key Performance Indicators ("KPIs")
The Board recognises the importance of both financial and non-financial KPIs in driving appropriate behaviours and enabling the monitoring of Group performance.
The key financial KPIs monitored by the Board are revenue, gross margin and EBITDA which are discussed under the review of the Income Statement above. In addition, the Board also reviews cash and working capital balances on a monthly basis.
Internal reporting and the review of non-financial KPIs has been enhanced during the year and are considered as measurements and targets for operational performance. These KPIs include the monitoring of samples activated, turnaround times and failure rates as well as customer feedback on platforms such as Trustpilot, the success of email marketing campaigns through open, click through and conversion rates and social media reach.
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
For The Year Ended
|
|
2024 |
2023 |
|
|
£'000 |
£'000 |
|
|
|
|
|
Revenue |
3,607 |
10,977 |
|
Cost of sales |
(3,801) |
(8,929) |
|
Gross (loss)/profit |
(194) |
2,048 |
|
Sales and marketing costs |
(627) |
(621) |
|
|
|
|
|
Other administrative expenses |
(1,355) |
(1,636) |
|
Redundancy costs |
- |
(114) |
|
Share based payments |
(54) |
(38) |
|
Administration expenses |
(1,409) |
(1,788) |
|
|
|
|
|
Operating loss |
(2,230) |
(361) |
|
Exceptional income |
206 |
- |
|
Finance income |
239 |
168 |
|
Finance expense |
(1) |
(2) |
|
Loss before income tax |
(1,786) |
(195) |
|
Tax credit |
- |
36 |
|
Loss for the year |
(1,786) |
(159) |
|
Other comprehensive income |
- |
- |
|
Total comprehensive loss for the year |
(1,786) |
(159) |
|
|
|
|
|
Attributable to owners of the parent: |
(1,786) |
(159) |
|
|
|
|
|
Loss per ordinary share - basic |
(3.45)p |
(0.31)p |
|
Fully diluted loss per ordinary share |
(3.45)p |
(0.31)p |
|
|
|
|
All activities relate to continuing operations.
CONSOLIDATED STATEMENT OF FINANCIAL POSITION
As at
|
|
2024 |
2023 |
|
|
£'000 |
£'000 |
|
Non-current assets |
|
|
|
Plant and equipment |
82 |
79 |
|
Right of use assets |
- |
50 |
|
Intangible assets |
1,353 |
1,462 |
|
Total non-current assets |
1,435 |
1,591 |
|
|
|
|
|
Current assets |
|
|
|
Inventories |
133 |
342 |
|
Trade and other receivables |
1,761 |
3,660 |
|
Cash and cash equivalents |
5,473 |
7,749 |
|
Total current assets |
7,367 |
11,751 |
|
|
|
|
|
Total assets |
8,802 |
13,342 |
|
|
|
|
|
Current liabilities |
|
|
|
Trade and other payables |
1,827 |
4,612 |
|
Lease liabilities |
- |
26 |
|
Total liabilities |
1,827 |
4,638 |
|
|
|
|
|
Net assets |
6,975 |
8,704 |
|
|
|
|
|
Share capital |
781 |
780 |
|
Employee Benefit Trust reserve |
(25) |
(25) |
|
Share premium account |
3 |
- |
|
Reverse acquisition reserve |
(6,044) |
(6,044) |
|
Retained earnings |
12,260 |
13,993 |
|
Total equity |
6,975 |
8,704 |
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
For the year ended
|
|
Share capital |
Employee Benefit Trust reserve |
Deferred shares |
Share Premium |
Capital redemption reserve |
Reverse acquisition reserve |
Retained earnings |
Total |
|
|
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
£'000 |
|
Equity as at |
780 |
- |
6,359 |
16,887 |
1,815 |
(6,044) |
(10,947) |
8,850 |
|
Loss for the year |
- |
- |
- |
- |
- |
- |
(159) |
(159) |
|
Total comprehensive loss |
- |
- |
- |
- |
- |
- |
(159) |
(159) |
|
Capital reduction |
- |
- |
(6,359) |
(16,887) |
(1,815) |
- |
25,061 |
- |
|
Employee Benefit Trust shares |
- |
(25) |
- |
- |
- |
- |
- |
(25) |
|
Share-based payments |
- |
- |
- |
- |
- |
- |
38 |
38 |
|
Equity as at |
780 |
(25) |
- |
- |
- |
(6,044) |
13,993 |
8,704 |
|
Loss for the year |
- |
- |
- |
- |
- |
- |
(1,786) |
(1,786) |
|
Total comprehensive loss |
- |
- |
- |
- |
- |
- |
(1,786) |
(1,786) |
|
Exercise of share options |
1 |
- |
- |
3 |
- |
- |
(1) |
3 |
|
Share-based payments |
- |
- |
- |
- |
- |
- |
54 |
54 |
|
Equity as at |
781 |
(25) |
- |
3 |
- |
(6,044) |
12,260 |
6,975 |
CONSOLIDATED STATEMENT OF CASH FLOWS
For The Year Ended
|
|
|
|
|
|
2024 |
2023 |
|
|
£'000 |
£'000 |
|
Cash flows from operating activities |
|
|
|
Loss before taxation |
(1,786) |
(195) |
|
Adjustments for: |
|
|
|
Non-cash movement in provisions and accruals |
- |
(1,165) |
|
Depreciation and amortization |
255 |
223 |
|
(Profit)/loss on sale of fixed assets |
(6) |
1 |
|
Finance expenses |
1 |
2 |
|
Finance income |
(239) |
(168) |
|
Share-based payments |
54 |
38 |
|
Adjusted operating loss before changes in working capital |
(1,721) |
(1,264) |
|
Changes in working capital |
|
|
|
Decrease in inventory |
209 |
942 |
|
Decrease/(increase) in trade and other receivables |
1,907 |
(2,366) |
|
(Decrease)/increase in trade and other payables |
(2,785) |
3,252 |
|
Cash (utilized)/generated in operations |
(2,390) |
564 |
|
Net interest received |
230 |
160 |
|
Net cashflows from operating activities |
(2,160) |
724 |
|
Investing activities |
|
|
|
Purchase of plant and equipment |
(31) |
(46) |
|
Proceeds from sale of fixed assets |
10 |
- |
|
Purchase of intangible assets |
(72) |
(521) |
|
Net cash flows used in investing activities |
(93) |
(567) |
|
Financing activities |
|
|
|
Purchase of Employee Benefit Trust shares |
- |
(25) |
|
Exercise of share options |
3 |
- |
|
Repayment of lease liability |
(26) |
(27) |
|
Net cash flows from financing activities |
(23) |
(52) |
|
Taxation |
|
|
|
Tax credit received |
- |
36 |
|
Net cashflows from taxation |
- |
36 |
|
Net change in cash and cash equivalents |
(2,276) |
141 |
|
Cash and cash equivalents at the beginning of the year |
7,749 |
7,608 |
|
Cash and cash equivalents at the end of the year |
5,473 |
7,749 |
NOTES TO THE FINANCIAL STATEMENTS
The notes to the Financial Statement are available in full in the Group Annual Report and Financial Statements which will be available shortly on the Company website: www.myhealthcheckedplc.com
Basis of preparation
The financial statements have been prepared in accordance with
Loss per share
|
|
2024 |
2023 |
|
Basic and diluted |
|
|
|
Loss after tax for the year |
|
|
|
Weighted average number of shares - basic |
52,006,836 |
52,005,932 |
|
Less shares held by the Employee Benefit Trust (weighted) |
(184,111) |
(34,804) |
|
Weighted average number of shares |
51,822,725 |
51,971,128 |
|
Weighted average number of shares - fully diluted* |
51,822,725 |
51,971,128 |
|
Loss per share |
3.45p |
0.31p |
|
Fully diluted loss per share |
3.45p |
0.31p |
*Due to the loss for the year ended
Basic earnings per share is calculated by dividing the loss attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the year. The weighted average number of shares excludes the shares held by the Employee Benefit Trust.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE